Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term outcomes after salvage radiotherapy for postoperative locoregionally recurrent non-small-cell lung cancer

  • Kim, Eunji (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Song, Changhoon (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Mi Young (Department of Radiation Oncology, Kyungpook National University Medical Center) ;
  • Kim, Jae-Sung (Department of Radiation Oncology, Seoul National University College of Medicine)
  • Received : 2016.08.28
  • Accepted : 2016.11.09
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The outcomes and toxicities of locoregionally recurrent non-small-cell lung cancer (NSCLC) patients treated with curative radiotherapy were evaluated in the modern era. Materials and Methods: Fifty-seven patients receiving radical radiotherapy for locoregionally recurrent NSCLC without distant metastasis after surgery from 2004 to 2014 were reviewed. Forty-two patients were treated with concurrent chemoradiotherapy (CCRT), and 15 patients with radiotherapy alone. The median radiation dose was 66 Gy (range, 45 to 70 Gy). Lung function change after radiotherapy was evaluated by comparing pulmonary function tests before and at 1, 6, and 12 months after radiotherapy. Results: Median follow-up was 53.6 months (range, 12.0 to 107.5 months) among the survivors. The median overall survival (OS) and progression-free survival (PFS) were 54.8 months (range, 3.0 to 116.9 months) and 12.2 months (range, 0.8 to 100.2 months), respectively. Multivariate analyses revealed that single locoregional recurrence focus and use of concurrent chemotherapy were significant prognostic factors for OS (p = 0.048 and p = 0.001, respectively) and PFS (p = 0.002 and p = 0.026, respectively). There was no significant change in predicted forced expiratory volume in one second after radiotherapy. Although diffusing lung capacity for carbon monoxide decreased significantly at 1 month after radiotherapy (p < 0.001), it recovered to pretreatment levels within 12 months. Acute grade 3 radiation pneumonitis and esophagitis were observed in 3 and 2 patients, respectively. There was no chronic complication observed in all patients. Conclusion: Salvage radiotherapy showed good survival outcomes without severe complications in postoperative locoregionally recurrent NSCLC patients. A single locoregional recurrent focus and the use of CCRT chemotherapy were associated with improved survival. CCRT should be considered as a salvage treatment in patients with good prognostic factors.

Keywords

References

  1. Oh CM, Won YJ, Jung KW, et al. Cancer statistics in korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016;48:436-50. https://doi.org/10.4143/crt.2016.089
  2. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007;83:409-17. https://doi.org/10.1016/j.athoracsur.2006.08.046
  3. Hung JJ, Hsu WH, Hsieh CC, et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009;64:192-6. https://doi.org/10.1136/thx.2007.094912
  4. Endo C, Sakurada A, Notsuda H, et al. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg 2012;93:1061-8. https://doi.org/10.1016/j.athoracsur.2012.01.004
  5. Voltolini L, Paladini P, Luzzi L, Ghiribelli C, Di Bisceglie M, Gotti G. Iterative surgical resections for local recurrent and second primary bronchogenic carcinoma. Eur J Cardiothorac Surg 2000;18:529-34. https://doi.org/10.1016/S1010-7940(00)00572-8
  6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): non-small cell lung cancer. v4. 2016 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2016. [cited 2016 July 20]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nsclc.pdf.
  7. Kelsey CR, Clough RW, Marks LB. Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J 2006;12:283-8. https://doi.org/10.1097/00130404-200607000-00006
  8. Tada T, Fukuda H, Nakagawa K, et al. Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection. Int J Clin Oncol 2005;10:425-8. https://doi.org/10.1007/s10147-005-0526-5
  9. Cai XW, Xu LY, Wang L, et al. Comparative survival in patients with postresection recurrent versus newly diagnosed nonsmall-cell lung cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:1100-5. https://doi.org/10.1016/j.ijrobp.2009.03.017
  10. Bae SH, Ahn YC, Nam H, et al. High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. Yonsei Med J 2012;53:1120-7. https://doi.org/10.3349/ymj.2012.53.6.1120
  11. Bar J, Ng D, Moretto P, et al. Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis. Clin Lung Cancer 2013;14:200-4. https://doi.org/10.1016/j.cllc.2012.05.008
  12. Takenaka T, Takenoyama M, Toyozawa R, et al. Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer. Clin Lung Cancer 2015;16:51-6. https://doi.org/10.1016/j.cllc.2014.06.001
  13. Lee NK, Moon SH, Kim TH, et al. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection. Clin Lung Cancer 2013;14:399-406. https://doi.org/10.1016/j.cllc.2012.11.002
  14. Borst GR, De Jaeger K, Belderbos JS, Burgers SA, Lebesque JV. Pulmonary function changes after radiotherapy in non-smallcell lung cancer patients with long-term disease-free survival. Int J Radiat Oncol Biol Phys 2005;62:639-44. https://doi.org/10.1016/j.ijrobp.2004.11.029
  15. Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 1999;86:265-73. https://doi.org/10.1002/(SICI)1097-0142(19990715)86:2<265::AID-CNCR10>3.0.CO;2-B
  16. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall-cell lung cancer. N Engl J Med 1992;326:524-30. https://doi.org/10.1056/NEJM199202203260805
  17. O'Rourke N, Roque I Figuls M, Farre Bernado N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010:CD002140.
  18. Bille A, Pelosi E, Skanjeti A, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009;36:440-5. https://doi.org/10.1016/j.ejcts.2009.04.003

Cited by

  1. Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer vol.96, pp.47, 2017, https://doi.org/10.1097/md.0000000000008635
  2. Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids vol.8, pp.None, 2017, https://doi.org/10.3389/fonc.2018.00114
  3. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results vol.36, pp.12, 2017, https://doi.org/10.1007/s11604-018-0776-6
  4. A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer vol.18, pp.None, 2017, https://doi.org/10.1186/s12885-018-5039-5
  5. Salvage radiotherapy with simultaneous integrated boost in non small-cell lung cancer patients with mediastinal relapse after surgery: a pilot study vol.13, pp.1, 2017, https://doi.org/10.1186/s13014-018-1155-2
  6. Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer vol.51, pp.2, 2017, https://doi.org/10.4143/crt.2018.366
  7. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non‐small cell lung cancer: A virtual randomized phase III trial stratified by age vol.10, pp.6, 2017, https://doi.org/10.1111/1759-7714.13103
  8. Salvage stereotactic body radiotherapy for post-operative oligo-recurrence of non-small cell lung cancer: A single-institution analysis of 59 patients vol.19, pp.4, 2017, https://doi.org/10.3892/ol.2020.11407
  9. Radiotherapy for local recurrence of non-small-cell lung cancer after lobectomy and lymph node dissection-can local recurrence be radically cured by radiation? vol.50, pp.4, 2017, https://doi.org/10.1093/jjco/hyz188
  10. Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer vol.39, pp.1, 2017, https://doi.org/10.3857/roj.2020.01074
  11. Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience vol.39, pp.3, 2017, https://doi.org/10.3857/roj.2021.00696
  12. Virtual randomized study comparing lobectomy and particle beam therapy for clinical stage IA non-small cell lung cancer in operable patients vol.62, pp.5, 2021, https://doi.org/10.1093/jrr/rrab060
  13. Altered Wnt5a expression affects radiosensitivity of non‑small cell lung cancer via the Wnt/β‑catenin pathway vol.23, pp.1, 2021, https://doi.org/10.3892/etm.2021.10927